A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Not yet recruiting
University of Chicago
Phase 1
2021-10-01
The purpose of this research is to gather information on the safety and effectiveness of
fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib
(two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the
US Food and Drug Administration (FDA) has not approved the combination of these drugs for the
treatment of rare blood cancers that present Isocitrate dehydrogenase (IDH) mutations, and
therefore these drugs can only be given in a research study.
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Recruiting
Bristol-Myers Squibb
Phase 1/Phase 2
2021-11-09
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as
maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic
hematopoietic cell transplant (HCT).
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/Phase 2
2021-11-09
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as
maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic
hematopoietic cell transplant (HCT).
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Recruiting
Bristol-Myers Squibb
Phase 2
2021-12-15
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a
study drug called fedratinib in participants with myelodysplastic/myeloproliferative
neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
